ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 151 filers reported holding ARGENX SE in Q4 2019. The put-call ratio across all filers is 0.59 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $305,793 | +0.9% | 622 | -50.2% | 0.01% | +100.0% |
| Q2 2023 | $303,069 | +403.0% | 1,250 | +97.5% | 0.01% | +133.3% |
| Q1 2023 | $60,250 | +66844.4% | 633 | -10.8% | 0.00% | +50.0% |
| Q4 2022 | $90 | -99.9% | 710 | +0.6% | 0.00% | 0.0% |
| Q3 2022 | $90,000 | +30.4% | 706 | +7.6% | 0.00% | 0.0% |
| Q2 2022 | $69,000 | -37.8% | 656 | -37.8% | 0.00% | +100.0% |
| Q1 2022 | $111,000 | -20.7% | 1,054 | +168.9% | 0.00% | -66.7% |
| Q4 2021 | $140,000 | +14.8% | 392 | -0.5% | 0.00% | +50.0% |
| Q3 2021 | $122,000 | -2.4% | 394 | -2.5% | 0.00% | -33.3% |
| Q2 2021 | $125,000 | +11.6% | 404 | 0.0% | 0.00% | +50.0% |
| Q1 2021 | $112,000 | +8.7% | 404 | +15.1% | 0.00% | -50.0% |
| Q4 2020 | $103,000 | +9.6% | 351 | +1.4% | 0.00% | -33.3% |
| Q3 2020 | $94,000 | +28.8% | 346 | +3.6% | 0.01% | 0.0% |
| Q2 2020 | $73,000 | +58.7% | 334 | -0.9% | 0.01% | +20.0% |
| Q1 2020 | $46,000 | -9.8% | 337 | +8.4% | 0.01% | +25.0% |
| Q4 2019 | $51,000 | – | 311 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SAL Trading, LLC | 36,100 | $17,747,843 | 24.88% |
| Artia Global Partners LP | 49,238 | $24,206,878 | 10.06% |
| Paradigm Biocapital Advisors LP | 261,443 | $128,533,222 | 8.72% |
| Darwin Global Management, Ltd. | 45,615 | $22,425,702 | 7.89% |
| Avoro Capital Advisors LLC | 1,000,000 | $491,630,000 | 7.67% |
| Bellevue Group AG | 911,530 | $448,135,494 | 7.22% |
| Eagle Health Investments LP | 64,400 | $31,660,972 | 6.98% |
| DCF Advisers, LLC | 22,000 | $10,815,860 | 5.89% |
| SAL Trading, LLC | 8,149 | $4,006,293 | 5.62% |
| RTW INVESTMENTS, LP | 507,195 | $249,352,278 | 5.26% |